Company News

Share this article:

Endo Pharmaceuticals announced a partnership with specialty pharma ProStrakan to commercialize the latter's Fortesta (testosterone gel) 2% in the US. FDA is currently reviewing an NDA for Fortesta, a hormone replacement therapy for male hypogonadism – a condition whereby male sex glands produce too little testosterone. Endo plans to market the product, upon FDA approval, alongside Nebido, an Endo hormone therapy injectable also under review at FDA.   

Behavioral science agency MicroMass Communications announced a partnership with Worldwide Partners, Inc. (WPI) to increase its reach internationally. WPI's network consists of 94 agencies for clients in 54 countries around the world. WPI is based in Denver, CO.

Abbott will collaborate with Pfizer on a molecular diagnostic test for the screening of non-small cell lung cancer tumors for the presence of gene rearrangements, according to a joint company statement. Abbott's molecular diagnostics business, headquartered in Des Plaines, IL, will develop the diagnostic tool necessary for identifying patients eligible for Pfizer's investigational agent (PF-02341066) that selectively targets cancer-causing genes, according to the statement.   


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.